Physician Awareness of the Cardiac Effects of Methadone

References

• U.S. Food and Drug Administration. Product Discontinuation Notice for ORLAAM® (Levomethadyl hydrocholoride acetate) Oral Solution, 10 mg/ml, CII 23 August 2003. Accessed at http://www.fda.gov/cder/whatsnew. htm on 12 October 2003.
   Google Scholar
• US Department of Health and Human Services . Substance Abuse and Mental Health Services Administration (SAMHSA) Accessed at http://www.samhsa.gov/ on 26 Feb 2003.
   Google Scholar
• Krantz , M J , Lewkowiez , L , Hays , H , Woodroffe , M A , Robertson , A D and Mehler , P S . 2002 . Torsade de pointes associated with very-high-dose methadone . Ann Intern Med. , 137 : 501 – 4 .
   PubMed Web of Science ®Google Scholar
• Ehret , G B , Vpode , C Gex-Fabru , M . 2006 . Drug-induced long QT syndrome in injection drug users receiving methadone . Arch Intern Med. , 166 : 1280 – 87 .
   PubMed Web of Science ®Google Scholar
• Martell , B A , Arnsten , J H , Krantz , M J and Gourevitch , M N . 2005 . Impact of methadone treatment on cardiac repolarization and conduction in opioid users . Am J Cardiol , 95 : 915 – 8 .
   PubMed Web of Science ®Google Scholar
• Faggiano , F , Vigna-Taglianti , F , Versino , E and Lemma , P . 2003 . Methadone maintenance at different dosages for opioid dependence . Cochrane Database Syst Rev , 3 CD002208
   Google Scholar
• Krantz , M J and Mehler , P S . 2006 . QT prolongation: methadone's efficacy-safety paradox . Lancet , 368 : 356 – 7 .
   Web of Science ®Google Scholar
• Drugs with risk of torsade de pointes . The University of Arizona Center for Education and Research on Therapeutics (CERT); Available at: http://www.torsades.org/med-prosdurg-lists/drug-lists.htm Last updated November3, 2006 Accessed November 20, 2006
   Google Scholar
• Thompson's MICROMEDEX(r). Available at: www.thomsonhc.com Accessed October 3, 2006
   Google Scholar
• Pearson , E C and Woosley , R L . 2005 . QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system . Pharmacoepidemiol Drug Saf. , 14 : 747 – 53 .
   PubMed Web of Science ®Google Scholar
• Lasser , K E , Allen , P D , Woolhandler , S J , Himmelstein , D U , Wolfe , S M and Bor , D H . 2002 . Timing of new black box warnings and withdrawals for prescription medications . JAMA , 287 : 2215 – 20 .
   PubMed Web of Science ®Google Scholar
• Substance abuse and mental health administration's treatment facility locator . Available at www.findtreatment.samhsa.gov Accessedon January 2, 2006
   Google Scholar
• Edwards , P , Roberts , I , Clark , M , DiGuiseppi , C , Pratap , S , Wentz , R and Kwan , I . 2002 . Increasing response rates to postal questionnaires: systematic review . BMJ , 324 : 1183
   PubMed Web of Science ®Google Scholar
• Everly , M J , Heaton , P C and Cluxton , R J Jr . 2004 . Betablocker underusein secondary prevention of myocardial infarction . Ann Pharmacother , 38 : 286 – 93 .
   PubMedGoogle Scholar
• Antman , E M , Lau , J Kupelnick , B . 1992 . A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts . JAMA , 268 : 240 – 8 .
   PubMed Web of Science ®Google Scholar
• D'Aunno , T and Pollack , H A . 2002 . Changes in methadone treatment practices: results from a national panel study, 1988–2000 . JAMA , 288 : 850 – 6 .
   PubMed Web of Science ®Google Scholar
• Wechsberg , W M , Flannery , B , Kasten , J J , Suerken , C , Dunlap , L , Roussel , A E , Crum , L , Murdoch , O and Diesenhaus , H . 2004 . Physicians practicing in methadone treatment programs: who are they and what do they do? . J Addict Dis. , 23 : 15 – 31 .
   PubMed Web of Science ®Google Scholar
• Joe , G W , Simpson , D D , Dansereau , D F and Rowan-Szal , G A . 2001 . Relationships between counseling rapport and drug abuse treatment outcomes . Psychiatr Serv. , 52 : 1223 – 9 .
   PubMed Web of Science ®Google Scholar
• CSAT Guidelines for the accreditation of opioid treatment programs, DRAFT Available at http://dpt.samhsa.gov/pdfdraft_accred_guidelines.pdf. Accessed November 15, 2006
   Google Scholar
• Viskin , S . 1999 . Long QT syndromes and torsade de pointes . Lancet , 354 : 1625 – 33 .
   PubMed Web of Science ®Google Scholar
• Krantz , M J , Rowan , S B and Mehler , P S . 2005 . Cocaine-related torsade de pointes in a methadone maintenance patient . J Addict Dis. , 24 : 53 – 60 .
   PubMed Web of Science ®Google Scholar
• Krantz , M J , Garcia , J A and Mehler , P S . 2005 . Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes . Pharmacotherapy , 25 : 611 – 14 .
   PubMed Web of Science ®Google Scholar
• Ballesteros , M F , Budnitz , D S , Sanford , C P , Gilchrist , J , Agyekum , G A and Butts , J . 2003 . Increase in deaths due to methadone in North Carolina . JAMA , 290 : 40
   PubMed Web of Science ®Google Scholar
• Maine Drug-Related Mortality Patterns: 1997–2002 . Available at: http://www.state.me.us/ag/pr/drugreport.pdf Accessed November 10, 2006
   Google Scholar
• Gagajewski , A and Apple , F S . 2003 . Methadone-related deaths in Hennepin County, Minnesota: 1992–2002 . J Forensic Sci. , 48 : 1 – 4 .
   Web of Science ®Google Scholar
• Drug Abuse Warning Network . 2006 . Opiate related drug misuse deaths in six states: 2003 19 The DAWN report.
   Google Scholar
• U.S. Food and Drug Administration Methadone Hydrolcholoride. FDA Alert [11/2006]: Death, Narcotic Overdose, and Serious Cardiac Arrhythmias. Available at: http://www.fda.gov/cder/drug/advisory/methadone.htm. Accessed November 29, 2006
   Google Scholar
• Roden , D M . 2004 . Drug-induced prolongation of the QT interval . N Engl J Med. , 350 : 1013 – 22 .
   PubMed Web of Science ®Google Scholar
• Langendam , M W , van Brussel , G H , Coutinho , R A and van Ameijden , E J . 2001 . The impact of harm-reduction-based methadone treatment among heroin users . Am J Pub Hlth. , 91 : 744 – 80 .
   Google Scholar